Mereo BioPharma Group (NASDAQ:MREO) Rating Increased to Hold at Lifesci Capital

Key Points

• Lifesci Capital upgraded Mereo BioPharma to a 'Hold'; analysts are mixed (four Buys, three Holds, one Sell) and the consensus rating is 'Hold' with an average price target of $3.25.
• Shares opened at $0.34 and were down about 5.2%, the company has a market cap of roughly $54.4M and a 52‑week range of $0.20–$3.05; it recently reported a quarterly EPS miss, raising near‑term funding and execution concerns.
• Mereo is still analyzing Phase 3 data for setrusumab, a potential long‑term value driver, but multiple ongoing securities class action filings add material legal and financial risk.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) was upgraded by Lifesci Capital to a "hold" rating in a research note issued to investors on Thursday,Zacks.com reports.

MREO has been the subject of a number of other reports. Jefferies Financial Group lowered shares of Mereo BioPharma Group from a "buy" rating to a "hold" rating in a research note on Tuesday, December 30th. Cantor Fitzgerald reissued an "overweight" rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Wall Street Zen cut shares of Mereo BioPharma Group from a "hold" rating to a "sell" rating in a research report on Saturday, January 3rd. BTIG Research reiterated a "buy" rating and set a $1.00 price objective on shares of Mereo BioPharma Group in a research note on Friday, January 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Mereo BioPharma Group in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $3.25.

Mereo BioPharma Group Stock Down 5.2%

MREO opened at $0.34 on Thursday. The stock's fifty day moving average is $0.44 and its two-hundred day moving average is $1.31. The company has a market capitalization of $54.42 million, a P/E ratio of -5.70 and a beta of 0.34. Mereo BioPharma Group has a 52 week low of $0.20 and a 52 week high of $3.05.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last issued its earnings results on Thursday, March 19th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Equities analysts anticipate that Mereo BioPharma Group will post -0.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Virtus Investment Advisers LLC raised its stake in shares of Mereo BioPharma Group by 199.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 122,595 shares of the company's stock worth $51,000 after acquiring an additional 81,665 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in Mereo BioPharma Group in the fourth quarter worth $106,000. Quadrature Capital Ltd purchased a new position in Mereo BioPharma Group in the fourth quarter worth $111,000. EcoR1 Capital LLC acquired a new position in shares of Mereo BioPharma Group during the fourth quarter worth $3,274,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Mereo BioPharma Group during the fourth quarter worth $533,000. Hedge funds and other institutional investors own 62.83% of the company's stock.

More Mereo BioPharma Group News

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Company updates: Mereo published full‑year 2025 results and corporate highlights and said additional data analyses from the Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta are ongoing — a potential long‑term value driver if analyses produce positive signals. Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
• Negative Sentiment: Earnings miss: Mereo reported quarterly EPS of ($0.05), missing the consensus of ($0.01). The larger-than-expected loss likely pressured sentiment and raises near‑term funding and execution concerns for a small biotech with limited market cap. Quarterly Financial Results Press Release
• Negative Sentiment: Legal / litigation risk: Multiple plaintiff law firms have announced or publicized a securities class action covering ADS purchases from June 5, 2023 through Dec 26, 2025 and are soliciting lead plaintiffs (April 6, 2026 deadline). The proliferation of filings and solicitations (Rosen, Schall, Faruqi, Bronstein, Berger Montague, Pomerantz, DJS, etc.) increases uncertainty and could lead to costly litigation or settlements. Rosen Law Firm Notice Bronstein, Gewirtz & Grossman Notice Faruqi & Faruqi Notice

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo's pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.